Oxperial BioHealth: Engineering Herbal Nutrition Into Measurable Science

Oxperial BioHealth is pioneering a new category of herbal supplementation they call “daylight active” nutrition — science-engineered formulations designed to enhance biological function more effectively, including through interaction with daylight. As part of the Alethios Early-Stage Program, Oxperial recently completed its first structured human study, incorporating wearable data and inflammation biomarkers to detect early signal with greater rigor than typically accessible to young supplement companies.

We spoke with founder Daniel Chen about their mission, why human evidence matters, and what it means to build credibility from the start.

Briefly describe Oxperial's mission and the human health problem you’re working to solve.

Daniel Chen:
Oxperial’s mission is to bring to market higher-purity herbal supplements and reinvent how herbal nutrition works by moving supplements toward what we call “daylight active” science-engineered efficacy.

Today, billions of people take supplements for immune and long-term health. Yet most products have low absorption, limited impact, and very little human evidence behind them. Consumers are essentially asked to trust without proof.

We’re solving this by developing “daylight active” — or photodynamic — nutrition. These are supplements designed to enhance biological function more effectively, including through interaction with daylight, so people can achieve meaningful health benefits with purer, better-engineered herbal nutrients.

When you think about building trust in a health product, what role does human evidence play for you?

Daniel Chen:
Human evidence is foundational. In health, consumers don’t just buy ingredients — they buy belief and confidence. And belief must be earned through building evidence.

Preclinical science explains mechanism, but human studies demonstrate relevance. They show that a product doesn’t just work in theory, but in real physiology and daily life.

For Oxperial, human evidence bridges three things: scientific credibility, regulatory trust, and consumer confidence.

What has it been like to get a structured study up and running as an early-stage team?

Daniel Chen:
It’s been both challenging and transformative.

As an early-stage company, you’re balancing speed, cost, scientific rigour, and operational reality all at once. Most clinical pathways are slower, expensive, and infrastructure-heavy — which can be difficult before large funding rounds.

Running a structured study forced us to sharpen how we think about product claims, positioning, and long-term validation strategy. So while it was challenging, it’s also been strategically valuable. It changes how you operate internally.

What made Alethios feel like the right partner to support this study?

Daniel Chen:
Alethios felt aligned from the beginning. They understand startups — the pace, the constraints, and the need for practicality.

They’re incredibly responsive, collaborative, and genuinely care about enabling credible science in emerging health companies.

Their ethos around accessible, well-designed human studies that are easier for both participants and companies resonated strongly with us.

What have you appreciated about not needing traditional clinical infrastructure to run this study?

Daniel Chen:
The flexibility has been critical.

Being able to run a structured, real-world human study without heavy site infrastructure allowed us to move faster, stay capital-efficient, and still maintain methodological integrity.

From our perspective, for nutrition and wellness products, real-world human data is often more relevant than tightly controlled clinical environments. Supplements are used in daily life — so measuring them in daily life makes sense.

What would you tell another early-stage health founder who’s considering running their first human study?

Daniel Chen:
Start early.

You don’t need a pharma-scale trial to begin generating human evidence. Well-designed, focused studies can already create scientific credibility and strategic clarity.

And just as importantly — work with partners who understand early-stage realities.

How could this study help with funding for the company in the future?

Daniel Chen:
We believe human data changes how users and investors evaluate health innovation.

In supplements, it’s often a crowded market. Human evidence allows you to shift the narrative from “another product” to “validated technology.” It moves you toward evidence-backed health technology.

That expands the type of serious customers and investors you can engage. It fundamentally changes the conversation.

With their first structured study completed and analysis underway through an Alethios in-network PI, Oxperial is building not just a supplement — but an evidence-backed platform from day one.

‍